Please Wait.....
Report
Middle East and Africa Dengue Treatment Market
Market Report I 2024-06-01 I 179 Pages I Data Bridge Market Research
Middle East and Africa dengue treatment market is expected to reach USD 116.81 million by 2031, from USD 49.55 million in 2023, growing at the CAGR of 11.3% in the forecast period of 2024 to 2031.
Market Segmentation:
Middle East and Africa Dengue Treatment Market, By Strains (DENV-2, DENV-3, DENV-1, DENV-4, and Others), Type (Vaccines and Acetaminophen), Severity (Mild to Moderate Dengue and Severe Dengue), Route of Administration (Parenteral and Oral), Mode of Purchase (Prescription and Over-the-Counter (OTC)), Gender (Male and Female), Age (Adult, Pediatric, and Geriatric), End User (Hospital, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Countries (South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Overview of Middle East and Africa Dengue Treatment Market Dynamics:
Driver
- Rising dengue incidence rate result in the demand for effective treatment
Restrain
- Delay in the approval process of vaccines
Opportunity
- Growing number of pipeline vaccines for dengue treatment
Market Players:
The key market players operating in the Middle East and Africa dengue treatment market are listed below:
- Sanofi
- Viatris Inc.
- Johnson & Johnson
- GSK plc.
- Baxter
- Fresenius Kabi USA
- Pfizer
- Hikma Pharmaceuticals PLC
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceuticals USA, Inc.
- Aurobindo Pharma
1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET 17
1.4 CURRENCY AND PRICING 19
1.5 LIMITATIONS 19
1.6 MARKETS COVERED 20
2 MARKET SEGMENTATION 23
2.1 MARKETS COVERED 23
2.2 GEOGRAPHICAL SCOPE 24
2.3 YEARS CONSIDERED FOR THE STUDY 25
2.4 DBMR TRIPOD DATA VALIDATION MODEL 26
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29
2.6 MULTIVARIATE MODELLING 30
2.7 MARKET APPLICATION COVERAGE GRID 31
2.8 PRODUCT LIFELINE CURVE 32
2.9 DBMR MARKET POSITION GRID 33
2.10 VENDOR SHARE ANALYSIS 34
2.11 SECONDARY SOURCES 35
2.12 ASSUMPTIONS 35
3 EXECUTIVE SUMMARY 36
4 PREMIUM INSIGHTS 39
4.1 PESTEL ANALYSIS 40
4.2 PORTER'S FIVE FORCES 41
5 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: REGULATIONS 42
5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT 43
5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT 43
5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK 44
5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE 44
5.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK 45
?
6 MARKET OVERVIEW 46
6.1 DRIVERS 48
6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT 48
6.1.2 RISING WAVE OF DENGUE VACCINE LAUNCHES 48
6.1.3 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS 49
6.1.4 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES 50
6.2 RESTRAINTS 51
6.2.1 DELAY IN THE APPROVAL PROCESS OF VACCINES 51
6.2.2 LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE 52
6.2.3 DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE 53
6.3 OPPORTUNITIES 54
6.3.1 STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET 54
6.3.2 GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT 54
6.3.3 RISING R&D INVESTMENT AND ACTIVITIES 55
6.4 CHALLENGES 56
6.4.1 HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS 56
6.4.2 HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS 56
7 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS 58
7.1 OVERVIEW 59
7.2 DENV-2 62
7.3 DENV-3 62
7.4 DENV-1 63
7.5 DENV-4 63
7.6 OTHERS 64
8 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TYPE 65
8.1 OVERVIEW 66
8.2 VACCINES 69
8.2.1 DENGVAXIA (CYD-TDV) 70
8.2.2 QDENGA 70
8.3 ACETAMINOPHEN 70
8.3.1 PARENTERAL 71
8.3.2 ORAL 71
8.3.3 OTHER 71
?
9 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY SEVERITY 72
9.1 OVERVIEW 73
9.2 MILD TO MODERATE DENGUE 76
9.3 SEVERE DENGUE 76
10 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 77
10.1 OVERVIEW 78
10.2 PARENTERAL 81
10.2.1 SUB-CUTANEOUS 81
10.2.2 INTRAVENOUS 81
10.3 ORAL 82
10.3.1 TABLET 82
10.3.2 CAPSULES 82
10.3.3 OTHERS 82
11 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE 83
11.1 OVERVIEW 84
11.2 PRESCRIPTION 87
11.3 OVER-THE-COUNTER (OTC) 87
12 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY GENDER 88
12.1 OVERVIEW 89
12.2 MALE 92
12.3 FEMALE 92
13 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY AGE 93
13.1 OVERVIEW 94
13.2 ADULT 97
13.3 PEDIATRIC 97
13.4 GERIATRIC 98
14 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY END USER 99
14.1 OVERVIEW 100
14.2 HOSPITAL 103
14.3 SPECIALTY CLINICS 103
14.4 HOME HEALTHCARE 104
14.5 OTHERS 104
?
15 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 105
15.1 OVERVIEW 106
15.2 RETAIL PHARMACIES 109
15.3 HOSPITAL PHARMACIES 109
15.4 ONLINE PHARMACIES 110
16 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY REGION 111
16.1 MIDDLE EAST AND AFRICA 114
16.1.1 EGYPT 120
16.1.2 SAUDI ARABIA 125
16.1.3 SOUTH AFRICA 130
16.1.4 U.A.E 135
16.1.5 ISRAEL 140
16.1.6 REST OF MIDDLE EAST AND AFRICA 145
17 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: COMPANY LANDSCAPE 146
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
18 SWOT ANALYSIS 147
19 COMPANY PROFILE 148
19.1 SANOFI 148
19.1.1 COMPANY SNAPSHOT 148
19.1.2 REVENUE ANALYSIS 148
19.1.3 COMPANY SHARE ANALYSIS 149
19.1.4 PRODUCT PORTFOLIO 149
19.1.5 RECENT DEVELOPMENTS 149
19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED 150
19.2.1 COMPANY SNAPSHOT 150
19.2.2 REVENUE ANALYSIS 150
19.2.3 COMPANY SHARE ANALYSIS 151
19.2.4 PRODUCT PORTFOLIO 151
19.2.5 RECENT DEVELOPMENTS 151
19.3 VIATRIS INC. 153
19.3.1 COMPANY SNAPSHOT 153
19.3.2 REVENUE ANALYSIS 154
19.3.3 COMPANY SHARE ANALYSIS 154
19.3.4 PRODUCT PORTFOLIO 154
19.3.5 RECENT DEVELOPMENTS 155
19.4 JOHNSON & JOHNSON SERVICES, INC. 156
19.4.1 COMPANY SNAPSHOT 156
19.4.2 REVENUE ANALYSIS 156
19.4.3 COMPANY SHARE ANALYSIS 157
19.4.4 PRODUCT PORTFOLIO 157
19.4.5 RECENT DEVELOPMENT 157
19.5 GSK PLC. 159
19.5.1 COMPANY SNAPSHOT 159
19.5.2 REVENUE ANALYSIS 159
19.5.3 COMPANY SHARE ANALYSIS 160
19.5.4 PRODUCT PORTFOLIO 160
19.5.5 RECENT DEVELOPMENTS 160
19.6 AUROBINDO PHARMA 161
19.6.1 COMPANY SNAPSHOT 161
19.6.2 REVENUE ANALYSIS 161
19.6.3 PRODUCT PORTFOLIO 162
19.7 BAXTER 163
19.7.1 COMPANY SNAPSHOT 163
19.7.2 REVENUE ANALYSIS 163
19.7.3 PRODUCT PORTFOLIO 164
19.8 FRESENIUS KABI USA 165
19.8.1 COMPANY SNAPSHOT 165
19.8.2 PRODUCT PORTFOLIO 165
19.8.3 RECENT DEVELOPMENTS 165
19.9 HIKMA PHARMACEUTICALS 166
19.9.1 COMPANY SNAPSHOT 166
19.9.2 REVENUE ANALYSIS 166
19.9.3 PRODUCT PORTFOLIO 167
19.9.4 RECENT DEVELOPMENT 167
19.10 PERRIGO COMPANY PLC 168
19.10.1 COMPANY SNAPSHOT 168
19.10.2 REVENUE ANALYSIS 168
19.10.3 PRODUCT PORTFOLIO 169
19.10.4 RECENT DEVELOPMENT 169
19.11 PFIZER INC. 170
19.11.1 COMPANY SNAPSHOT 170
19.11.2 REVENUE ANALYSIS 170
19.11.3 PRODUCT PORTFOLIO 171
19.11.4 RECENT DEVELOPMENTS 171
?
19.12 SUN PHARMACEUTICAL INDUSTRIES LTD 172
19.12.1 COMPANY SNAPSHOT 172
19.12.2 REVENUE ANALYSIS 173
19.12.3 PRODUCT PORTFOLIO 173
19.12.4 RECENT DEVELOPMENT 173
19.13 TEVA PHARMACEUTICALS USA, INC. 174
19.13.1 COMPANY SNAPSHOT 174
19.13.2 REVENUE ANALYSIS 174
19.13.3 PRODUCT PORTFOLIO 175
19.13.4 RECENT DEVELOPMENT 175
20 QUESTIONNAIRE 176
21 RELATED REPORTS 179
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security